ArticleGynecologic oncology reports2025
Patient with HR-proficient advanced ovarian cancer achieved a complete response with Cadonilimab combined chemotherapy (PD-1/CTLA-4 bispecific): a case report and literature review.
Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A narrative review of new strategies for immunotherapy combination treatment in platinum-resistant ovarian cancer: mechanisms, clinical evidence, and future directions.Frontiers in oncology · 2026Review
- PD-L1-negative triple-negative breast cancer exhibited a remarkable response to cadonilimab: a case report.Frontiers in oncology · 2026Article
- Advances in PD-1 and CTLA-4 dual-target immunotherapy for ovarian cancer.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: For advanced ovarian cancer (OC), particularly OC with HR-deficient, surgery combined with adjuvant chemotherapy and maintenance therapy with PARPi/bevacizumab is the standard effective first-line treatment regimen. However, the clinical benefit of therapy for HR-proficient advanced OC is limited, with no significant increase in the 5-year survival rate. Methods: In this case study, a patient with Stage IVB OC, who tested HR-proficient, but PD-L1 positive, experienced significant tumor shrinkage (>90 %) after undergoing 3 cycles of neoadjuvant chemotherapy using TC (Paclitaxel with Carboplatin) with Cadonilimab (a PD-1/CTLA-4 bispecific antibody) therapy. Results: This resulted in an R0 resection during intermittent debulking surgery. After surgery, while the patient received standard first-line chemotherapy with TC + bevacizumab, the CA125 level failed to normalize. Nonetheless, upon readministration of Cadonilimab, CA125 levels normalized and have been maintained to date. The patient has remained free of recurrence and metastasis for more than 23 months after neoadjuvant therapy, before the data cutoff date, March 10, 2025. Conclusions: This case illustrates that individuals suffering from advanced OC, particularly those with HR-proficient and PD-L1 positive status, may benefit from first-line treatment with Cadonilimab. Identifying the population that may benefit from immune therapy is crucial. The novel PD-1/CTLA-4 bispecific antibody merits further attention for managing advanced epithelial ovarian cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.